Advertisement

Central European Journal of Medicine

, Volume 7, Issue 5, pp 650–654 | Cite as

Severe aplastic anemia in a patient with rheumatoid arthritis after introduction of etanercept

  • Yoshiro Horai
  • Tomoya Miyamura
  • Karin Shimada
  • Motoko Ishida
  • Soichiro Takahama
  • Rumi Minami
  • Masahiro Yamamoto
  • Eiichi Suematsu
Case Report
  • 129 Downloads

Abstract

A 73-year-old female, diagnosed with rheumatoid arthritis (RA), complicated with severe levels of joint destruction, started etanercept (ETN) because of high persistent RA disease activity. Although her articular symptoms dramatically improved, she developed marked pancytopenia after the introduction of ETN. Bone marrow aspirate specimen revealed hypocellular marrow in three hematopoietic series without atypical findings, which was compatible with aplastic anemia (AA). This is a rare case of severe pancytopenia due to AA presumably induced by ETN.

Keywords

Aplastic anemia Rheumatoid arthritis Etanercept 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    van der Heijde D, Klareskog L, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum, 2006, 54: 1063–1074PubMedCrossRefGoogle Scholar
  2. [2]
    Katikireddi VS, Whittle SL, Hill CL. Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis. Int J Rheum Dis, 2010, 13: 12–26PubMedCrossRefGoogle Scholar
  3. [3]
    Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum, 2009, 61: 305–312PubMedCrossRefGoogle Scholar
  4. [4]
    Jurisic V, Bogdanovic G, Kojic V, Jakimov D, Srdic T. Effect of TNF-alpha on Raji cells at different cellular levels estimated by various methods. Ann Hematol. 2006, 85, 86–94PubMedCrossRefGoogle Scholar
  5. [5]
    Miyasaka N, Takeuchi T, Eguchi K. Guidelines for the proper use of etanercept in Japan. Mod Rheumatol, 2006, 16: 63–67PubMedCrossRefGoogle Scholar
  6. [6]
    Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol, 2009, 36: 898–906PubMedCrossRefGoogle Scholar
  7. [7]
    Takeuchi T, Amano K. Etanercept (in Japanese). Nippon Rinsho, 2002, 60: 2390–2396PubMedGoogle Scholar
  8. [8]
    Kaushik P, Rahmani M, Ellison W. Membranous glomerulonephritis with the use of etanercept in ankylosing spondylitis. Ann Pharmacother, 2011, 45:e62PubMedCrossRefGoogle Scholar
  9. [9]
    Baumelou E, Guiguet M, Mary JY. Epidemiology of aplastic anemia in France: a case-control study. I. Medical history and medication use. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood, 1993, 81:1471–1478PubMedGoogle Scholar
  10. [10]
    Pathare SK, Heycock C, Hamilton J. TNFalpha blocker-induced thrombocytopenia. Rheumatology (Oxford), 2006, 45:1313–1314CrossRefGoogle Scholar
  11. [11]
    Jurisic V, Terzic T, Pavlovic S, Colovic N, Colovic M. Elevated TNF-alpha and LDH without parathormone disturbance is associated with diffuse osteolytic lesions in leukemic transformation of myelofibrosis. Pathol Res Pract. 2008, 204, 129–132PubMedCrossRefGoogle Scholar
  12. [12]
    Kuruvilla J, Leitch HA, Vickars LM, Galbraith PF, Li CH, Al-Saab S, et al. Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol, 2003, 71: 396–398PubMedCrossRefGoogle Scholar
  13. [13]
    Balandraud N, Guis S, Meynard JB, Auger I, Roudier J, Roudier C. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis. Arthritis Rheum, 2007, 57: 762–767PubMedCrossRefGoogle Scholar
  14. [14]
    Komatsuda A, Wakui H, Nimura T, Sawada K. Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. Mod Rheumatol, 2008, 18, 315–318PubMedCrossRefGoogle Scholar
  15. [15]
    Ueda M, Tateishi T, Shigeto H, Yamasaki R, Ohyagi Y, Kira J. A case of acute disseminated encephalomyelitis associated with Epstein-Barr virus reactivation during infliximab therapy (in Japanese). Rinsho Shinkeigaku, 2010, 50: 461–466PubMedCrossRefGoogle Scholar
  16. [16]
    Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP Jr. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood, 1997, 89:256–260PubMedGoogle Scholar
  17. [17]
    Bowman SJ, Sivakumaran M, Snowden N, et al. The large granular lymphocyte syndrome with rheumatoid arthritis. Immunogenetic evidence for a broader definition of Felty’s syndrome. Arthritis Rheum. 1994, 37, 1326–1330PubMedCrossRefGoogle Scholar
  18. [18]
    Hart DN, Baker BW, Inglis MJ, et al. Epstein-Barr viral DNA in acute large granular lymphocyte (natural killer) leukemic cells. Blood, 1992, 79: 2116–2123PubMedGoogle Scholar
  19. [19]
    Kim TH, Choi SJ, Lee YH, Song GG, Ji JD. Soluble triggering receptor expressed on myeloid cells-1 as a new therapeutic molecule in rheumatoid arthritis. Med Hypotheses. 2012, 78, 270–272PubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Yoshiro Horai
    • 1
  • Tomoya Miyamura
    • 1
  • Karin Shimada
    • 1
  • Motoko Ishida
    • 1
  • Soichiro Takahama
    • 1
  • Rumi Minami
    • 1
  • Masahiro Yamamoto
    • 1
  • Eiichi Suematsu
    • 1
  1. 1.Department of Internal Medicine and Rheumatology, Clinical Research Center, National HospitalOrganization Kyushu Medical CenterFukuokaJapan

Personalised recommendations